HER2-positive gastric cancer
Clinical trials for HER2-positive gastric cancer explained in plain language.
Never miss a new study
Get alerted when new HER2-positive gastric cancer trials appear
Sign up with your email to follow new studies for HER2-positive gastric cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trio takes aim at HER2-Positive stomach cancer
Disease control Recruiting nowResearchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for stomach cancer: phase 3 trial tests rilvegostomig combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a targeted cancer drug deliver in the real world?
Disease control Recruiting nowThis observational study is tracking 260 adults in China with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants are receiving trastuzumab deruxtecan (T-DXd) as part of their routine care, and researchers are collecting …
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) works better for people with advanced HER2-positive stomach or gastroesophageal junction cancer. About 550 participants will be randomly assigned to rece…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 1/2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC